An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) (NCT05649748)
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Who can join: Review the eligibility criteria below.
Location: USA005 — Jacksonville, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- USA005 — Jacksonville, Florida
- USA011 — Tampa, Florida
- USA006 — Chicago, Illinois
- USA001 — Chicago, Illinois
- USA102 — New York, New York
- USA016 — Dallas, Texas
- ARG009 — Quilmes, Buenos Aires
- ARG006 — Rosario, Santa Fe Province
- ARG007 — San Miguel de Tucumán, Tucumán Province
- ARG004 — Córdoba,
- ARG001 — Córdoba,
- AUT002 — Linz, Upper Austria
- AUT001 — Vienna,
- BEL003 — Brussels,
- BRA004 — Belo Horizonte, Minas Gerais
- BRA006 — Porto Alegre, Rio Grande do Sul
- BRA002 — Blumenau, Santa Catarina
- DNK001 — Aarhus, Central Jutland
- GER005 — Heidelberg, Baden-Wurttemberg
- GER003 — München, Bavaria
- GER002 — Lübeck, Schleswig-Holstein
- ITA002 — Pavia, Lombardy
- ITA005 — Monza,
- ITA001 — Palermo,
- ITA004 — Roma,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) — Aurora, Colorado
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Phoenix, Arizona
- Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Aurora, Colorado
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California
Explore by condition: All Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.